000 | 01991 a2200589 4500 | ||
---|---|---|---|
005 | 20250517055317.0 | ||
264 | 0 | _c20160726 | |
008 | 201607s 0 0 eng d | ||
022 | _a2213-1787 | ||
024 | 7 |
_a10.1016/j.jchf.2015.05.012 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWohlfahrt, Peter | |
245 | 0 | 0 |
_aAssociation of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure. _h[electronic resource] |
260 |
_bJACC. Heart failure _cOct 2015 |
||
300 |
_a829-39 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Observational Study; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAbsorptiometry, Photon _xmethods |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
650 | 0 | 4 | _aBiomarkers |
650 | 0 | 4 | _aChronic Disease |
650 | 0 | 4 | _aCohort Studies |
650 | 0 | 4 | _aEchocardiography, Doppler |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aFibroblast Growth Factor-23 |
650 | 0 | 4 |
_aFibroblast Growth Factors _xblood |
650 | 0 | 4 |
_aHeart Failure, Systolic _xblood |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aKaplan-Meier Estimate |
650 | 0 | 4 |
_aKidney Failure, Chronic _xetiology |
650 | 0 | 4 | _aKidney Function Tests |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aMultivariate Analysis |
650 | 0 | 4 | _aPredictive Value of Tests |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aRetrospective Studies |
650 | 0 | 4 | _aRisk Assessment |
650 | 0 | 4 | _aSeverity of Illness Index |
650 | 0 | 4 | _aSurvival Analysis |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aMelenovsky, Vojtech | |
700 | 1 | _aKotrc, Martin | |
700 | 1 | _aBenes, Jan | |
700 | 1 | _aJabor, Antonin | |
700 | 1 | _aFranekova, Janka | |
700 | 1 | _aLemaire, Sophia | |
700 | 1 | _aKautzner, Josef | |
700 | 1 | _aJarolim, Petr | |
773 | 0 |
_tJACC. Heart failure _gvol. 3 _gno. 10 _gp. 829-39 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jchf.2015.05.012 _zAvailable from publisher's website |
999 |
_c25337638 _d25337638 |